SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (1192)4/12/1999 4:40:00 PM
From: sim1  Read Replies (1) | Respond to of 1826
 
This abstract may be posted elsewhere but I couldn't find it.
I'm guessing this is related to the ASCO presentation in May. It's scheduled for 8am tomorrow morning.

[PROC. AMER. ASSOC. CANCER RES. 40, March 1999]
Copyright © 1999 by the American Association for Cancer Research

#3224 Induction of apoptosis in prostate tumor cells by hydroxymethylacylfulvene (HMAF) and oxaliplatin (Ox-Pt).Woynarowska, B.A., Higdon, A.L., Munoz, R.M. and Woynarowski, J.M. The University of Texas Health Science Center, San Antonio, TX 78248 and Cancer Therapy and Research Center, San Antonio, TX 78245.

Targeting apoptosis is particularly relevant to prostate cancer since it is a disease of impeded cell death rather than of accelerated growth. This investigation evaluated pro-apoptotic properties of two novel clinical antitumor drugs, hydroxymethylfulvene (HMAF) and oxaliplatin. HMAF growth inhibitory activity (GI50 of 0.03 - 0.35 µM) against 6 human prostate cell lines correlated with drug uptake. Oxaliplatin was less potent than HMAF (GI50 of 0.2 - 5 µM). Time and concentration-dependent induction and progression of apoptosis by HMAF and Ox-Pt was observed in all tumor prostate cell lines. The level of induced apoptosis as measured by DNA fragmentation and multivariate flow cytometry, depended on cell line and decreased with androgen dependency of cells. Apoptosis by HMAF was accompanied by reactive oxygen species (ROS) generation and a modest release of cytochrome C (~2 fold increase over control after 4 h with 25 µM HMAF). Ox-Pt did not cause cytochrome C leakage to the cytoplasm. HMAF induced apoptosis was not preceded by caspase-3 activation and was not affected by caspase-3 inhibitors. It was abrogated, however, by a broad-spectrum caspase inhibitor Z-VAD-fmk. The results suggest the potential of HMAF and Ox-Pt as apoptosis targeting agents in prostate cancers.

Previous | Next | Search

Schedule: 4/13/1999 8:00 a.m.



To: scaram(o)uche who wrote (1192)4/14/1999 9:14:00 PM
From: LLCF  Read Replies (2) | Respond to of 1826
 
< However, there's always ASCO next month.>

So you have the dates...? After MOGN, and ONXX I'm not about to miss some call buying on the deriv thread before that one!

DAK